Skip Navigation



Annals of Oncology Advance Access published online on June 24, 2005
Annals of Oncology, doi:10.1093/annonc/mdi282
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/9/1503    most recent
mdi282v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Italiano, A.
Right arrow Articles by Michiels, J.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Italiano, A.
Right arrow Articles by Michiels, J.-F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received April 1, 2005
Revised May 10, 2005
Accepted May 12, 2005

Original article

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications

A. Italiano 1*, M.-C. Saint-Paul 2, F.-X. Caroli-Bosc 3, E. François 1, A. Bourgeon 3, D. Benchimol 3, J. Gugenheim 3, and J.-F. Michiels 2

1 Centre Regional de Lutte Contre le Cancer Antoine-Lacassagne, Department of Medical Oncology, Nice France
2 Centre Hospitalier Universitaire de Nice, Hôpital Pasteur, Department of Pathology, Nice France
3 Centre Hospitalier Universitaire de Nice, Hôpital Archet 2, Medical-Surgical Department of Gastrointestinal Oncology and Hepatology, Nice, France

* To whom correspondence should be addressed.
A. Italiano, E-mail: antoineitaliano{at}cario.fr


  Abstract

Background: Epidermal growth factor receptor (EGFR) plays an important role in the pathogenesis of colorectal cancer (CRC). There are several potential strategies to target EGFR. However, monoclonal antibodies and low molecular weight tyrosine kinase inhibitors are the most advanced in clinical development. The majority of studies so far have merely required EGFRs to be expressed by CRC cells. The detection of EGFR expression is usually performed by immunohistochemistry (IHC) in the primary tumor. There are few data regarding the EGFR status in the corresponding distant metastases.

Patients and methods: EGFR status was analyzed by IHC in 80 patients (31 male, 49 female) with CRC (70 colon, 10 rectum) and at least one distant metastatic lesion. Metastatic sites analyzed (n=80) were liver (79 patients) and lung (one patient).

Results: EGFR reactivity was similar in the primary tumor and the related metastases. Among the 80 paired primary/metastatic tumors, only five (6.3%) showed discordance in EGFR status: two cases with EGFR expression in the primary tumor but not in the metastasis, and three samples with EGFR expression in the metastasis but not in the primary tumor.

Conclusions: Between the paired primary tumors and distant metastatic lesions, 94% of samples had concordant EGFR status when analyzed by IHC.

Keywords: colorectal cancer; epidermal growth factor receptor; targeted therapies.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. Yamada, Y. Ichikawa, S. Yamagishi, N. Momiyama, M. Ota, S. Fujii, K. Tanaka, S. Togo, S. Ohki, and H. Shimada
Amphiregulin Is a Promising Prognostic Marker for Liver Metastases of Colorectal Cancer
Clin. Cancer Res., April 15, 2008; 14(8): 2351 - 2356.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Italiano, F. B. Vandenbos, J. Otto, J. Mouroux, D. Fontaine, P.-Y. Marcy, N. Cardot, A. Thyss, and F. Pedeutour
Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors
Ann. Onc., June 1, 2006; 17(6): 981 - 985.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.